Korean J Med.  2002 Nov;63(5):557-561.

Four cases of ticlopidine-induced cholestatic hepatitis

• Han J
• Kim MH
• Moon HK
• Kang KT
• Cha KS
• Kim YD
• Kim JS

Abstract

Ticlopidine, a potent antiplatelet agent, is widely used for treatment of coronary artery disease and cerebrovascular disease. Adverse effects has been reported in 10% to 20% of patients receiving ticlopidine. The most commom adverse effects were gastrointestinal disturbance, skin rash, but cholestatic hepatitis with jaundice was rare (0.1% incidence). We have recently experienced four cases of ticlopidine-induced cholestatic hepatitis after coronary artery stent insertion. Jaundice developed within 1 month of starting ticlopidine at recommended daily doses. In all cases, jaundice resolved and serum liver enzymes improved over a period of months after drug withdrawal. Therefore, clinicians should be aware of the reversible condition of ticlopidine-induced cholestatic jaundice that slowly resolves after drug withdrawal.

Keyword

Ticlopidine; Cholestatic hepatitis; Jaundice

MeSH Terms

Coronary Artery Disease
Coronary Vessels
Exanthema
Hepatitis*
Humans
Jaundice
Jaundice, Obstructive
Liver
Stents
Ticlopidine
Ticlopidine